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CObjectives: Health-care costs for the treatment of skin cancers are dis-
proportionately high in many white populations, yet they can be re-
duced through the promotion of sun-protective behaviors. We investi-
gated the lifetime health costs and benefits of sunscreen promotion in the
primary prevention of skin cancers, includingmelanoma. Methods: A de-
ision-analytic model with Markov chains was used to integrate data
rom a central community-based randomized controlled trial con-
ucted in Australia and other epidemiological and published sources.
ncremental cost per quality-adjusted life-year was the primary out-
ome. Extensive one-way and probabilistic sensitivity analyses were
erformed to test the uncertainty in the base findings with plausible
ariation to the model parameters. Results: Using a combined house-
old and government perspective, the discounted incremental cost per
uality-adjusted life-year gained from the sunscreen intervention was O
o rep
ealt
al So
oi:10.1016/j.jval.2011.10.009U$40,890. Over the projected lifetime of the intervention cohort, this
ould prevent 33 melanomas, 168 cutaneous squamous-cell carcino-
as, and 4 melanoma-deaths at a cost of approximately AU$808,000.
he likelihood that the sunscreen interventionwascost-effectivewas64%
t awillingness-to-pay threshold ofAU$50,000per quality-adjusted life-year
ained.Conclusions: Subject to the best-available evidence depicted in
ur model, the active promotion of routine sunscreen use to white
opulations residing in sunny settings is likely to be a cost-effective
nvestment for governments and consumers over the long term.
eywords: cost-effectiveness, health-care costs, melanoma, primary
revention, squamous-cell carcinoma, sunscreen.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In predominantly fair-skinned populations living in high sunlight
environments, the treatment costs for skin cancers exert a signif-
icant financial burden on the health-care system. Cutaneous ma-
lignant melanoma is the most deadly skin cancer, causing more
than 8000 deaths in the United States [1] and more than 1200
deaths in Australia each year [2]. Although seldom fatal, the sheer
quantity of basal-cell carcinoma (BCC) and squamous-cell carci-
noma (SCC) in these populations causes disproportionately more
resources to be expended on these cancers than on any other [3–5].
In the United States, skin cancer treatments cost an estimated $2
billion each year. In addition are costs of other sun-related skin
conditions such as actinic keratoses (AKs), which range in preva-
lence from 6% to 25% in the United Kingdom and United States [6]
to 40% to 60% in Australia [6,7], and are one of the strongest pre-
dictors of skin cancer [7]. Management of AKs accounts for an
additional $1.2 billion in health-care costs in the United States [8].
The evidence that the vast majority of skin cancers are caused
by solar ultraviolet radiation (UVR) exposure is accepted [9]. Both
acute and chronic overexposure to the sun, including early in life,
are important for the development of skin cancers including mel-
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ublished by Elsevier Inc.anoma [10] and it is thus expected that their prevention is achiev-
able through the engagement of sun-protective behaviors. On this
basis, wearing sun-protective clothing, broad-brimmed hat and
sunglasses, and seeking shade is recommended by health author-
ities inmanyWestern countries [11–13]. The topical application of
broad-spectrum sunscreens is also recommended as a safe ad-
junct measure in protecting human skin from UVR damage and
cancer development [14,15].
Australia has the highest reported rates of skin cancer in the
world, with two in three Australians being diagnosed with skin
cancer in their lifetime and more than 1600 deaths attributed to
skin cancer each year [5,16]. Not surprisingly, Australia has led the
world in the development of sun-protectionmessages and promo-
tional campaigns such as Slip Slop Slap and SunSmart and these
programs appear to have successfully raised public awareness and
improved preventive behaviors [17,18], even slowing melanoma
and other skin cancer incidence rates in younger cohorts [19].
It is plausible then that health-care costs could be reduced
through interventions promoting sun-protection behaviors. Be-
causemany skin cancers are treated in relatively low-cost primary
care settings, however, some have suggested that it is more eco-
nomical to treat these conditions as they arise rather than invest-
ing in preventive measures that promote sun protection [20]. Re-
ort.
h Economics, Griffith University, University Drive, Meadowbrook
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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262 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 6 1 – 2 6 8futing this with community-based trial data [15], we have shown
that a sunscreen intervention provided a practical means of pre-
venting SCCs and produced significant cost-savings for govern-
ment health providers [21]. The question remained, however,
whether these cost-effective benefits could bemaintained into the
longer term when melanoma, the least prevalent but more often
fatal form of skin cancer, was taken into account. Therefore, the
purpose of this study was to investigate the potential health costs
and benefits of a sunscreen intervention over the longer term (re-
maining lifetime) with respect to melanoma prevention in addi-
tion to the previously demonstrated benefits.
Methods
Description of strategies
The strategies modeled were based on the Nambour Skin Cancer
Prevention Trial [22–24] where 1621 residents of Nambour in
ueensland, Australia, were randomized to either the sunscreen
ntervention group or the control group. The intervention group
as encouraged to apply a broad-spectrum Sun Protection Factor
5 sunscreen to their head, neck, arms, and hands every morn-
ng (“daily use” group) and received one or more 250-mL bottles of
unscreen free of charge every 3 months at dedicated study clin-
cs. The control group participants were instructed to use sun-
creen at their own discretion (“discretionary use” group). All par-
icipants received full skin examinations by dermatologists
naware of treatment allocation, at the start (1992), midway
1994), and at the end (1996) of the trial. Any clinically diagnosed
kin cancers were confirmed by pathology reports. Participants
ho withdrew from active trial participation or active follow-up
ere asked to continue with ongoing “passive” monitoring of skin
ancers through their medical records [25]. After the trial ended in
996, all participants, including those who withdrew from active
ollow-up, consented to have subsequently diagnosed skin can-
ers notified to the investigators by regional pathology laborato-
ies in Queensland. Finally, a cross-check for any melanomas di-
gnosed between 1992 and 2006 in study participants was
ndertaken through a search of cancer notifications at the
ueensland Cancer Registry [26].
Overview of model structure
A decision-analytic model with Markov chains was constructed in
TreeAge Pro 2009 software (TreeAge Software, Inc., Williamstown,
MA) (Fig. 1). Themodel trackedmultiple hypothetical cohorts sep-
arately to examine the health and cost outcomes of individuals
with different profiles. Male, female, or mixed-sex cohorts with a
mean starting age of 49 years (i.e., the mean age of participants at
commencement of the Nambour Skin Cancer Trial) were modeled
until age 100 years or death. Key measures in the model included
time since diagnosis, costs, number of melanomas, quality-ad-
justed life-years (QALYs) and life-years lived. Guidelines for best-
practice procedures for economic modeling were adhered to dur-
ing our study [27].
Health states and transition probabilities
The model consists of seven health states—no melanoma; mela-
noma (in situ); melanoma (stage I); melanoma (stage II); mela-
noma (stage III); melanoma (stage IV); and dead—with staging de-
fined by the American Joint Committee on Cancer categories [28].
All cohort members begin the model without a melanoma. Indi-
viduals will either continue to live without a melanoma or be di-
agnosed with amelanoma (and treated accordingly based on their
American Joint Committee on Cancer stage). Following treatment,
individuals diagnosed with melanoma face stage-specific risks of
remaining in remission, having a recurrence, a diagnosis of addi- stional tumors, distant metastases, or death. In all health states,
individuals also face an age-specific all-causemortality risk. Time-
dependent probabilities have been built into the model to ensure
that the risk of cancer progression, recurrence, or death is depen-
dent on the duration since diagnosis.
Melanoma stage and incidence rates are the average of the
latest three years of Australian melanoma incidence data by age
and gender [29] (Table 1). An age-specific risk of melanoma was
used in themodel, and a constant hazard ratio from sunscreen use
applied to this risk. Therefore, the absolute risk reduction (risk
difference) is age dependent.
Evidence for the effectiveness of daily sunscreen use in pre-
ventingmelanomawas sourced from theNambour study [26] where
Cox proportional-hazards regression was performed to estimate the
hazard ratio for melanoma development in relation to daily sun-
screenuse comparedwithdiscretionary use. Intention-to-treat anal-
ysis was carried out for all reviewed and histologically confirmed
melanomas between 1993 and 2006 [26]. The protective effect from
sunscreen was statistically significant for invasive melanoma (0.27;
95% confidence interval [CI] 0.08–0.97) [26]. There were no signifi-
ant differences in sun-protection behaviors (time spent outdoors
n theweekend andweekdays, seeking of shade, and hatwearing)
ther than sunscreen use between the intervention and control
roups before and after the intervention.
Estimates of survival rates for melanoma patients were trans-
ormed into progression rates to late-stage cancer and subsequent
ortality [31]. The annual progression rates to stage IVmelanoma
rom stages I and II were steady at 2% and 7%, respectively. Stage
IImelanomas had a first-year progression rate of 45%, but it fell by
third each year thereafter. Mortality risk in year 1 of a stage IV
iagnosis was 42%, and it fell by approximately one-fifth each year
Fig. 1 – Schematic of melanoma-only model. Note: Patients
diagnosed with a melanoma of a specific stage may be
diagnosed with additional melanomas of the same or later
stage. Transition to a higher stage may be disease
progression or additional melanoma. Death may be
melanoma related or from any cause.ince diagnosis. Additionalmelanoma diagnoseswere assumed to
263V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 6 1 – 2 6 8Table 1 – Parameter estimates used in the model and sources.
Model parameter Mean* Low High Distribution Source
Starting age of cohort (y) 49 25 75 Normal [25]
Discount rate for costs 0.05 0 0.07 – –
Discount rate for effects 0.05 0 0.07 – –
Annual hazard ratio of invasive melanoma for
sunscreen users
0.27 0.08 0.97 Log normal [26]
Probability that melanoma is invasive 0.631 0.628 0.636 Beta [19]
Probability that second melanoma is invasive 0.8 0.76 0.84 Beta [30]
Invasive melanomas stage I @ diagnosis 0.34 – – Dirichlet [31]
Invasive melanomas stage II @ diagnosis 0.52 – – Dirichlet [31]
Invasive melanomas stage III @ diagnosis 0.07 – – Dirichlet [31]
Invasive melanomas stage IV @ diagnosis 0.07 – – Dirichlet [31]
Annual SCC risk 0.015 0.013 0.018 Beta [25]
Rate ratio of SCC for sunscreen users 0.59 0.38 0.9 Log normal [25]
Annual risk of progression from stage I to stage IV 0.02 0.015 0.026 Beta [31]
Annual risk of progression from stage II to stage IV 0.07 0.051 0.092 Beta [31]
First-year risk of progression from stage III to stage IV 0.45 0.32 0.58 Beta [31]
Annual decay in stages III–IV progression risk 0.3 0.15 0.45 – [31]
First-year mortality risk for stage IV melanoma† 0.42 0.22 0.54 Beta [31]
Annual decay in stage IV mortality risk 0.2 0.1 0.3 – [31]
Age- and sex-specific background mortality rate Life table – – – [32]
Age- and sex-specific melanoma risk Table – – Beta [29]
Time-dependent risk of second melanoma Table – – Beta [30]
Utilities
No melanoma‡ 1 0.5 1 Beta –
Melanoma in situ @ diagnosis§ 0.95 0.5 1 Beta –
Melanoma—stage I @ diagnosis 0.937 0.5 1 Beta [33]
Melanoma—stage II @ diagnosis 0.753 0.5 1 Beta [33]
Melanoma—stage III @ diagnosis 0.52 0.5 1 Beta [33]
Melanoma—stage IV @ diagnosis 0.47 0.3 1 Beta [34]
Melanoma in situ—stable disease 1 0.5 1 Beta –
Melanoma—stage I—stable disease 0.96 0.5 1 Beta [35]
Melanoma—stage II—stable disease 0.93 0.5 1 Beta [36]
Melanoma—stage III—stable disease 0.93 0.5 1 Beta [36]
Melanoma—stage IV—stable disease 0.65 0.5 1 Beta [37]
Dead 0 – – – –
Costs (AU$)
HH: Discounted lifetime melanoma costs 3300 1650 4950 Gamma [38]
HH: Annual “daily use” sunscreen out-of-pocket costs¶ 25.14 13 38 Gamma [21]
HH: Annual “discretionary use” sunscreen out-of-
pocket costs¶
24.92 13 38 Gamma [21]
Govt: Annual intervention program cost per person# 80.7 40 121 Gamma [21]
Govt: Cost to diagnose and treat stage I melanoma in
first year
2496 1248 3744 Gamma [37]
Govt: Cost to diagnose and treat stage II melanoma in
first year
5544 2772 8316 Gamma [37]
Govt: Cost to diagnose and treat stage III melanoma in
first year
19,644 9822 29,466 Gamma [37]
Govt: Ongoing annual costs for stages II and III
melanoma
2685 1343 4028 Gamma [37]
Govt: Cost to diagnose and treat stage IV melanoma in
first year
30,122 15,061 45,183 Gamma [37]
Govt: End-of-life/palliative care costs in stage IV
melanoma
5472 2736 8208 Gamma [37]
Govt: Treatment cost for SCC 420 210 630 Gamma [21]
Govt, government; HH, household; SCC, squamous-cell carcinoma.
* All rates from the data are converted into annual transition probabilities by using the transformation equation 1 EXP(RATE).
† Preferences for health states are assumed to be constant across all ages.
‡ Melanoma survival is presumed to be independent of age.
§ Complications during treatment are not explicit in utility estimates but will be accounted for with the beta distribution.
 Household costs.
¶ Includes time spent applying sunscreen and visits to skin clinics.
# Includes the provision of free sunscreen.
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264 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 6 1 – 2 6 8be either the same American Joint Committee on Cancer stage or
later than the first primary melanoma diagnosis.
A second version of themodelwas created by incorporating the
protective effect of sunscreen on SCC development (0.59 relative
risk [RR]; 95% CI 0.38–0.90) [25] in addition to melanoma. The po-
tential for an SCC diagnosis wasmodeled as a possible occurrence
in every cycle except in individuals with stage IV melanoma. Be-
cause a significant protective effect of sunscreen in preventing
BCCs was not observed in the trial (0.87; 95% CI 0.64–1.2) [25], we
did not model this.
Estimates of health outcomes
Health outcomes measured by the model included QALYs, counts
of melanomas and SCCs, andmelanoma-related deaths. Mortality
risk from melanoma but not SCC was included in the model be-
cause SCCs rarelymetastasize and cause death. Similarly, because
there is insufficient evidence of decreases in quality of life for
SCCs, these outcomes are also omitted from themodel. QALYs are
calculated by using preference-based quality-of-life scores,
known as utility estimates. The health-related utility estimates
used in the model were derived from standard-gamble surveys
[34,35], time trade-off surveys [33], and expert opinion [39]. QALYs
were discounted by 5% per year.
Estimates of resource use and costs
The study considered a societal (household and government
health provider) perspective for measuring resource use. The re-
sources required from households and governments were also
presented separately. Health provider resources included staffing,
monitoring, and provision of sunscreen during clinics and the sub-
sequent health-care costs of diagnosing, treating, and following
up any suspicious skin lesions. Household costs included time and
out-of-pocket costs for applying sunscreen and attending clinic
visits and a discounted lifetime cost following melanoma diagno-
sis [35]. Intervention (government and household) and SCC and
CC treatment costs were extracted from a detailed cost-analysis
f the Nambour Skin Cancer Trial [21]. Several adjustments were
made to take account of cost efficiencies when doctors treated
more than one cancer in the same sitting andwhen benign lesions
were treated provisionally as suspected cancers [21]. Melanoma
diagnosis and treatment costs were sourced from a previous Aus-
tralian study ofmelanoma treatments [37]. All costs (Table 1) were
inflated to 2010 prices based on the Australian Bureau of Statistics
cost of health inflation (AU$1  US$0.85) [40]. Costs were dis-
counted at 5% per year.
Analyses
The total lifetime costs and outcomes for each strategy were esti-
mated, and the incremental cost-effectiveness ratio (ICER) was
calculated. We assumed a willingness-to-pay threshold of
AU$50,000 per QALY gained. In Australia, although there is no
fixed threshold, evidence shows that interventions showing ICERs
of up to AU$50,000 per QALY are considered cost-effective [41]. A
ne-way sensitivity analyses was undertaken where each of the
Table 2 – Discounted costs and QALYs per person by interv
Discretionary use
Costs (AU$) QALYs Costs (A
Melanoma only 1420 16.12 2451
Melanoma  SCC 1522 16.12 2512
ICER, incremental cost-effectiveness ratio; SCC, squamous-cell carcinodel parameters was varied through a range of plausible values(Table 1) and changes to the base results observed. During the
sensitivity analysis, the threshold values for key parameters were
identified, below (or above) which the sunscreen intervention
would be considered cost-effective at AU$50,000 perQALY. Aprob-
abilistic sensitivity analysis was also performed by resampling
2000 times at random from assigned probability distributions for
each parameter. Log-normal distributions were used for the mel-
anomahazard ratio and SCC relative risk fromdaily sunscreen use
[42], gamma distributions were used for all cost estimates, and
beta distributions were used for probabilities and utility scores.
Where data were unavailable, it was assumed that the relative
standard deviation of the distributionwas 15% of themean, which
was also tested in the sensitivity analysis.
Results
Base case
Based on themean values of themodel parameters over the partici-
pants’ lifetimes, the discounted incremental cost per QALY gained
from daily use of sunscreen was AU$42,600 when considering the
protective effect for melanoma only. When the protective effect for
SCCs was included in the model, the ICER was AU$40,900 per QALY
gained (Table 2; costs and outcomes per person).
Additional outcomes (not discounted) from sunscreen use were
also estimated and costs were separated as accruing to government
orhouseholdsbasedonthesamenumberofparticipants in theNam-
bour Skin Cancer Trial (Table 3). We estimated that the program of
promotion of daily sunscreen use would prevent 168 SCCs, 33 mela-
nomas, and 4melanoma-related deaths in the intervention group at
an additional cost of AU$808,000 to society. It is estimated that if the
cohort had a starting age of 25 years, the interventionwould prevent
282 SCCs, 38 melanomas, and 5 melanoma-related deaths at an ad-
ditional cost of AU$995,600 to society. The cohort with a starting age
of 60 yearsmay see the prevention of 119 SCCs, 26melanomas, and 3
melanoma-related deaths at an additional cost of AU$775,500 to so-
ciety.
Sensitivity analyses
The most influential model parameters on the results of the com-
bined melanoma and SCC model were the incidence of melanoma,
the hazard ratio for invasivemelanoma, government and household
program costs, and discount rates (Table 4, Fig. 2). Holding other pa-
rameters constant, the daily sunscreen use strategy remained cost-
effective for individuals aged between 38 and 64 years, when the
hazard ratio in relation to sunscreen use was no greater than 0.37 or
the annual melanoma risk was at least 0.09%. Figure 3 shows the
results from the probabilistic sensitivity analysis as a trade-off be-
tween increased costs and increased effectiveness and the percent-
ageof incremental cost andeffect pairings that are belowa threshold
of AU$50,000 per QALY. In the model of melanoma only, the likeli-
hood that the promotion of daily sunscreen use is cost-effective was
64% (Fig. 3).
The very high ICER from the probabilistic sensitivity analysis
(Table 5) is an artifact caused by the 95% CI limit of the hazard ratio
on group and incremental cost per QALY.
use Incremental ICER (AU$)
QALYs Costs (AU$) QALYs
16.14 1031 0.02 42,614
16.14 990 0.02 40,890
; QALY, quality-adjusted life-year.enti
Daily
U$)for melanoma (0.97) being very close to 1, indicating no protective
osts f
265V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 6 1 – 2 6 8effect. In iterations inwhich the sampledhazard ratio is almost 1, the
incremental effect is virtually zero.When a large incremental cost is
divided by aminiscule incremental effect, an extremely high ICER is
the result (close to AU$100million per QALY). The handfuls of itera-
tions inwhich thesenumbersoccurhavecaused themean ICER from
the probabilistic sensitivity analysis to inflate substantially. Theme-
dian probabilistic sensitivity analysis ICER ismuch closer to the base
ICER and remains cost-effective at the threshold of AU$50,000 per
QALY.
Discussion
Our model suggests that an intervention that promotes frequent
sunscreen use is likely to be a cost-effective investment in pre-
venting melanomas and SCCs over a lifetime. We predict that a
substantial number of melanomas and SCCs could be prevented
and that the intervention is within an acceptable cost-effective-
ness range for health interventions. Our results were sensitive to
several key model parameters, including the incidence of mela-
noma, thehazard ratio ofmelanoma fromdaily sunscreenuse, age
Table 3 – Projected lifetime costs* and cancers for the contr
Discretionary use (n
Government costs AU$481,344
Household costs AU$749,951
Time to attend skin exam§ AU$69,339
Time to apply sunscreen AU$538,712
Melanoma costs¶ AU$141,900
Melanomas 43
Melanoma deaths 5
SCCs 413
SCCs, squamous-cell carcinomas.
* Costs are discounted.
† Differences in totals are due to rounding.
‡ Figures in parentheses are cost savings.
§ Based on frequency and duration of skin examinations.
 Based on patient-level data of sunscreen use frequency.
¶ Based on a discounted lifetime tariff for melanoma management c
Table 4 – One-way sensitivity and threshold values for me
Variable Low
Discount rate – effects 0%
Discount rate – effects (cohort age  20 y) 0%
Utility for stable melanoma 0.5
Hazard ratio for invasive melanoma 0.08
Annual program cost per person (AU$) 30
Cohort start age (y) 25
Discount rate – costs 0%
Melanoma risk multiplier 0.75
Risk of distant metastases multiplier 0
SCC, squamous-cell carcinoma; QALY; quality-adjusted life-year.
* For parameters to which results were found to be sensitive.
† At willingness-to-pay threshold of AU$50,000 per QALY.
‡ Parameter values above which the strategy will be cost-effective.
§ Parameter values below which the strategy will be cost-effective
 A multiplier was used for time-dependent variables where age and riskof the target cohort, government and household program costs,
and discount rates for costs and effects. As expected, the cost-
effectiveness is improved if the incidence of melanoma or SCC
increases, or the hazard ratio for melanoma or intervention costs
decrease. A further finding from the sensitivity analysis was that
for a cohort starting age within the range of 38 to 64 years, the
strategy was within common bounds of acceptability for cost-ef-
fectiveness. Below age 38 years, the effect of discounting health
outcomes reduced the current value of perceived benefits. How-
ever, when outcomes were discounted at 3.9% per year or less,
the cost-effectiveness of daily sunscreen use for a cohort with a
starting age of 25 years was again within the acceptable thresh-
old.
Our findings are likely to be conservative for several reasons.
Ethically, the discretionary use group could not be given a pla-
cebo sunscreen and therefore its members continued applying
sunscreen at their usual discretionary frequency. However, this
has meant that we have estimated the effectiveness of the in-
tervention by using a pragmatic “real-life” scenario because it is
expected that fair-skinned populations will be using sunscreen
d intervention groups.
9) Daily use (n  812) Difference†
AU$1,359,922 AU$878,578
AU$679,444 (AU$70,507)‡
AU$74,370 AU$5031
AU$572,074 AU$33,362
AU$33,000 (AU$108,900)
10 (33)
1 (4)
245 (168)
or a household.
ma and SCC model*.
Base High Threshold for daily
use to be cost-
effective†
Min‡ Max§
5% 7% 5.9%
5% 7% 3.9%
– 1 0.986
0.27 0.97 0.371
81 120 92.80
49 75 38 64
5% 7% 3.79%
1 1.25 0.865
0.5 1.5 0.576ol an
 80lanochanged annually.
266 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 6 1 – 2 6 8in some capacity. While the reduced incidence of SCC in the
daily sunscreen use group was included in the model, the qual-
ity of life and mortality risk from SCC was not included because
of a lack of evidence. Similarly, we took a conservative approach
by omitting the potentially protective effect of sunscreen for
BCCs and the known protective effect on AKs [7]. While a lower
incidence of BCC during the trial was observed in the daily sun-
screen use group (2474 per 100,000 person-years at risk) com-
pared with the discretionary use group (2840 per 100,000 per-
son-years at risk), this was not statistically significant and
therefore not included in themodel. In addition, the appearance
of subsequent BCCs was delayed in the daily sunscreen group
compared with the discretionary use group [43]. Conversely, a
Fig. 2 – Melanoma and squamous-cell carcinoma model—va
parameters. gov, government; ICER, incremental cost-effecti
Fig. 3 – Scatter plot of probabilistic sensitivity analyses resu
QALY, quality-adjusted life-year; WTP, willingness to pay.statistically significant protective effect of sunscreen for AKs
had been observed [7], but it was omitted from the model be-
cause of the complexity of AK epidemiology and because their
presence is a marker of skin cancer risk (which has already been
modeled). AK distribution in the population is highly skewed,
with most individuals having none and a small proportion hav-
ing many. The natural history of AKs is one of multiplicity and
high turnover, which makes it almost impossible to monitor
their true incidence [44]. Since AKs in their own right do not
represent a substantial disease burden per se, introducing AKs
to themodel would have had no impact on outcomes, but would
have resulted in fewer treatment costs, further improving the
cost-effectiveness of sunscreen.
on from base ICER* with plausible range of influential
ss ratio. *Base ICER is AU$40,890.
r the melanoma and squamous-cell carcinoma model.riati
venelts fo
s
s
t
c
a
h
e
p
267V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 6 1 – 2 6 8It is important to note that very few QALYs were gained by
the daily sunscreen use intervention, primarily because of the
presentation of mostly early-stage melanomas and subsequent
high survival rates of melanoma, the low incidence of mela-
noma relative to SCC and BCC, and the effect of discounting
future benefits. Despite this marginal gain in QALYs and the
conservative approach taken with respect to the above-men-
tioned factors, the strategy remained cost-effective. This is
likely to be heavily influenced by the future costs avoided for
treatment of melanomas and SCCs.
The evidence from our study suggests that regular sunscreen
use is likely to provide aworthwhile investment for government in
preventing skin cancer. The transformation of this single-site in-
tervention to a population-wide policy will have implications for
the measurement and attribution of costs. For example, the mod-
eled intervention provided free sunscreen for participants, which
is not practicable for a population-wide policy; however, evidence
suggests that the cost of purchasing sunscreen is only a minor
factor in explaining lower sunscreen use [45]. As such, therewould
be some cost shifting from the government to households for the
purchase of sunscreen, although the cost-effectiveness of the
strategy should not be affected significantly. The administration
involved with the follow-up for and provision of regular skin ex-
aminations for trial participants is another component of the trial
that would not be practicable to expand to a state or national level.
Therefore, it is likely that a population-wide intervention is likely
to cost less per person. At the very least, our findings provide clear
support for targeted sunscreen-promotion interventions, such as
the Nambour Skin Cancer Trial, at a local level. The results from
this study also suggest that state or national interventions that
result in moderate increases in sunscreen use may also be cost-
effective. In the United Kingdom, a country with a substantially
lower skin cancer incidence than Australia, the National Institute
for Clinical Excellence has issued public health guidance recom-
mending increased use of sunscreen at school andwork to prevent
skin cancer [46].
Prior to the publication of Green et al.[26], evidence supporting
sunscreen’s protective effect from melanoma was inconsistent
[47], and some considered the precautionary principle an appro-
priate rationale for recommending the use of sunscreen [48]. To-
gether with themore recent evidence of sunscreen’s effectiveness
[26] and safety [49], this study adds an economic aspect and in-
ights by demonstrating that it is also cost-effective. Our study has
everal drawbacks, however. First, much of UVR exposure is
hought to occur early in life [50], and so sun protection in younger
ohorts may be more effective in the long term [10], but this is not
reflected in our results because of discounting of outcomes. This is
a common bias against preventive measures that realize benefits
later in life. Including an evidence-based estimate of the lag be-
tween UVR exposure and carcinogenesis may offset this bias to
some extent. Evidence that sun-protection behaviors in later life
have a beneficial effect remains nonetheless [51]. Second, as with
all economic decision models, a number of simplifications and
assumptions were necessary. Although we have justified and ex-
plicitly documented these assumptions, a level of uncertainty re-
mains and reflects the evidence gaps in the etiology of skin cancer
development. Further evidence is required to consolidate the
Table 5 – Incremental cost-effectiveness ratios from probab
Mean ICER*(AU$)
Melanoma only 724,825
Melanoma  SCC 724,702
ICER, incremental cost-effectiveness ratio; SCC, squamous-cell carcin
* Per QALY.long-term protective effects of sunscreen. Finally, our model hasnot addressed the issue of the adequacy of UV exposure with reg-
ular sunscreen use in relation to vitamin D production [52]. There
is evidence, however, that vitamin D deficiency is not induced by
regular sunscreen use [53] and deficiency primarily occurs in the
elderly, or in dark skinned or obese people for reasons unrelated to
sunscreen use [54].
To the best of our knowledge, with the exception of our earlier
work on BCC and SCC prevention [21], only one research group has
investigated the cost-effectiveness of skin cancer prevention
through a widespread, multifaceted sun protection campaign
[55,56]. The study performed amodeling analysis of investment in
the SunSmart program involving a suite of public education strat-
egies (media, school accreditation, structural and environmental
changes across workplace and sport settings). Although the over-
all cost-effectiveness of sun protection was also clearly estab-
lished by Shih et al. [55], our study is different in that we rely on
patient-level data from a pragmatic randomized trial and have
undertaken a more micro assessment of costs including the addi-
tional costs of managing suspicious benign lesions. Unlike Shih et
al’s [55] study,we observe a stronger link between the intervention
nd health outcomes but do not incorporate the widespread
ealth-promoting approaches of SunSmart. The two studies, how-
ver, are very complementary in providing sound economic sup-
ort for sun-protection investments.
Conclusions
The incidence of skin cancer, including melanoma, is a serious
public health concern causing substantial losses in quality of life
andmortality. Based on estimated costs and benefits of daily sun-
screen use with data from a pragmatic randomized controlled
trial, our study provides assurance that promoting the use of sun-
screen is likely to be a cost-effective investment for governments
and households over the long term. Our findings provide support
for continued government investment in sun-protection cam-
paigns for populations in high-sunlight conditions to encourage
sunscreen use for protection from intense UV exposure.
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